Neuroprotection with Statin Therapy for Acute Recovery Trial (Neu START):A Phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke [SPOTRIAS] "NeuSTART II"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

Satisfies the criteria for ischemic stroke: acute focal neurological deficit of likely ischemic vascular origin; patient or legally authorized representative has provided written informed consent prior to study entry; patient can receive the first treatment dose within 0–24 hours of stroke onset(For patients found with stroke on awakening, it will be assumed that the stroke occurred the last time that the patient was known to be normal); patient has pretreatment brain CT scan compatible with ischemic stroke and excludes hemorrhagic and non-vascular etiologies of symptoms; patients taking statins at time of stroke may be included.

Exclusion Criteria

Brain imaging study shows a lesion other than ischemic stroke that could explain patient’s symptoms (intracranial or subarachnoid hemorrhage, arteriovenous malformation, aneurysm, multiple sclerosis, tumor, abscess or other). Asymptomatic meningiomas are allowed; mild stroke, defined as NIH Stroke Scale <2; patient has received or is expected to receive intravenous rt-PA within 3 hours or intra-arterial rt-PA within 6 hours of stroke onset, according to our institutional standard of care; receipt of intravenous rt-PA after 3 hours or intra-arterial rt-PA after 6 hours post-stroke onset; weight < 50 kg.; patient is comatose, regardless of etiology (> 4 points on the first three items of the NIHSS); history of intolerance or allergic reaction to any statins (myotoxicity, hepatic dysfunction, rash, etc.); use of drugs within past 30 days that utilize the cytochrome CYP3A pathway (cyclosporine, itraconazole, ketoconazole, erythromycin, azithromycin, clarithromycin, nefazodone); use of drugs within past 30 days that increase risk of myotoxicity with statins (gemfibrozil, other fibrates, niacin, amiodarone, verapamil); baseline major electrolyte disturbances (sodium <125 or >150, potassium <3.0 or >5.5); recent major trauma (<3 months); hypothermia (body temperature < 96ºF); baseline hypoxia (defined as oxygen saturation <92% on room air); history of likely or proven systemic viral infection within 30 days; known HIV infection or use of protease inhibitors; endocarditis likely as cause of stroke; mitochondrial disorder likely as cause of stroke; pregnancy or lactation; history of rhabdomyolysis, myopathy, or other severe muscle disease;history of hepatitis, decompensated liver disease (ascites, bleeding varices or encephalopathy), or liver failure; Liver function tests (ALT, AST) > 2 X upper limit of normal;unstable cardiovascular (includes uncontrolled hypertension), pulmonary, gastrointestinal, hepatic or musculoskeletal disease; patient has evidence of congestive heart failure or has history of end-stage cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina);abnormal ECG showing: Hemodynamically significant arrhythmia or frequent PVCs (>5/minute) (controlled atrial arrhythmia will not be an exclusion); evidence of acute myocardial infarction; Mobitz Type II 2nd degree AV block or 3rd degree AV block; ventricular tachycardia or ventricular fibrillation; significant renal insufficiency, indicated by serum creatinine >2.0 mg/dl.; hypoglycemia (glucose < 60 mg/dl) or diabetic ketoacidosis unresponsive to therapy;any of these hematologic abnormalities: Hb <10 g/dl; WBC <3.0 x 103/mm3; Platelet count <50,000/mm3; received an investigational drug within 30 days; severe behavioral or social problems that may interfere with the conduct of clinical study procedures; patient unlikely, in the investigator’s opinion, to complete the study and return for follow-up visits for any reason.